Recent News
On December 29, 2025 the company drew $75 million under a new five‑year credit facility from a major shareholder, repaid existing senior secured debt, and retained an option to draw up to $125 million total; the facility carries an 8.00% fixed rate and includes five‑year warrants. On December 11, 2025 an independent comparative analysis presented at a major hematology meeting concluded remestemcel‑L produced superior complete and overall remission outcomes versus ruxolitinib for steroid‑refractory acute graft‑versus‑host disease. On December 21, 2025 consensus one‑year price targets edged higher, lifting the average target to about $20.25.
Technical Analysis
ADX at 12.98 indicates no robust trend; directional momentum lacks strength, so price moves may consolidate until trend strength rises above the emerging range.
DI+ shows a dip‑and‑reverse and DI‑ shows a peak‑and‑reverse, both of which qualify as bullish directional shifts; the directional indicators therefore signal a transition toward buyer control despite ADX’s low strength reading.
MACD sits negative at −0.30 with the signal at −0.18, so momentum currently registers below the signal line; however a recent MACD dip‑and‑reversal signals improving momentum that has not yet completed a bullish cross above the signal line.
MRO reads 4.63 and recently reversed upward; the positive value implies price above target with modest overextension pressure, suggesting limited downside risk from immediate mean reversion but weak excess potential to force a sharp decline.
RSI at 51.1 shows a neutral posture with a recent dip‑and‑reversal toward higher readings, supporting the case for short‑term stabilization rather than a decisive breakout.
Price behavior versus averages: the close of $17.99 sits above the 200‑day average of $15.17 but below the 50‑day average of $18.14, indicating longer‑term strength with short‑term consolidation; the 12‑day EMA recently dipped then began to reverse upward, aligning with the improving short‑term momentum signals.
Bollinger bands place the stock inside the 1‑standard‑deviation band (lower $16.52; upper $18.80) with the close near the upper band, implying near‑term resistance overhead; the SuperTrend lower support registers at $16.06. Volume at 337,882 outpaced recent averages, suggesting conviction behind the latest move. Beta measures (42‑day 1.62; 52‑week 1.57) indicate above‑market volatility.
Fundamental Analysis
Revenue growth reads 20.50% (reported metric), while quarter‑over‑quarter and year‑over‑year revenue growth both report 0.0% in the supplied period metrics; the reported growth figure requires reconciling with the flat QoQ/YoY line items but does reflect a positive top‑line change in the provided growth metric.
Forward EPS equals $0.0425 producing a forward P/E of 403.51, markedly above the industry peer mean P/E of 29.71 and well above the industry peer median of −1.66; the forward P/E quarter‑over‑quarter change shows −4.78%.
Free cash flow totals $‑15,691,000 with free cash growth at 2.86% on the provided metric, while free cash growth shows QoQ −1.26% and YoY −1.81%, indicating negative absolute free cash flow accompanied by modest reported growth dynamics over the measured interval. Operating cash flow reports $0, beginning cash flow $144,719,000 and ending cash flow $129,975,000, a reduction of $14,744,000. Capital expenditures totaled $‑133,000 and invested capital stands at $‑33,001,000.
Cost of debt presents as 0.0% in the dataset, but the December 29 financing establishes an 8.00% fixed cost on the new facility drawn; the facility reduced prior secured leverage and supplies optional incremental liquidity through mid‑2026. WMDST values the stock as over‑valued based on the provided valuation metric and the wide gulf between forward P/E and industry peer mean and median.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-12-31 |
| REPORT DATE: | 2026-01-27 |
| NEXT REPORT DATE: | 2026-04-28 |
| CASH FLOW | Begin Period Cash Flow | $ 144.7 M |
| Operating Cash Flow | $ 0.00 | |
| Capital Expenditures | $ -133.00 K | |
| Change In Working Capital | — | |
| Dividends Paid | — | |
| Cash Flow Delta | $ -14.74 M | |
| End Period Cash Flow | $ 130.0 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | — | |
| Forward Revenue | — | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | — | |
| Depreciation and Amortization | — | |
| Research and Development | — | |
| Total Operating Expenses | — | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | — | |
| EBIT | — | |
| Operating Income | — | |
| Interest Income | — | |
| Interest Expense | — | |
| Net Interest Income | — | |
| Income Before Tax | — | |
| Tax Provision | — | |
| Tax Rate | — | |
| Net Income | — | |
| Net Income From Continuing Operations | — | |
| EARNINGS | ||
| EPS Estimate | — | |
| EPS Actual | — | |
| EPS Difference | — | |
| EPS Surprise | — | |
| Forward EPS | $ 0.04 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | — | |
| Intangible Assets | — | |
| Net Tangible Assets | — | |
| Total Current Assets | — | |
| Cash and Short-Term Investments | — | |
| Cash | — | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | — | |
| LIABILITIES | ||
| Accounts Payable | — | |
| Short-Term Debt | — | |
| Total Current Liabilities | — | |
| Net Debt | — | |
| Total Debt | — | |
| Total Liabilities | — | |
| EQUITY | ||
| Total Equity | — | |
| Retained Earnings | — | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | — | |
| Shares Outstanding | — | |
| Revenue Per-Share | — | |
| VALUATION | Market Capitalization | — |
| Enterprise Value | — | |
| Enterprise Multiple | — | |
| Enterprise Multiple QoQ | — | |
| Enterprise Multiple YoY | — | |
| Enterprise Multiple IPRWA | — | |
| EV/R | — | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | — | |
| Asset To Liability | — | |
| Debt To Capital | — | |
| Debt To Assets | — | |
| Debt To Assets QoQ | — | |
| Debt To Assets YoY | — | |
| Debt To Assets IPRWA | — | |
| Debt To Equity | — | |
| Debt To Equity QoQ | — | |
| Debt To Equity YoY | — | |
| Debt To Equity IPRWA | — | |
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | — | |
| Price To Book QoQ | — | |
| Price To Book YoY | — | |
| Price To Book IPRWA | — | |
| Price To Earnings (P/E) | — | |
| Price To Earnings QoQ | — | |
| Price To Earnings YoY | — | |
| Price To Earnings IPRWA | — | |
| PE/G Ratio | — | |
| Price To Sales (P/S) | — | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | — | |
| FORWARD MULTIPLES | ||
| Forward P/E | 403.507 | |
| Forward PE/G | — | |
| Forward P/S | — | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | — | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | — | |
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | — | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | — | |
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | — | |
| CapEx To Revenue | — | |
| CapEx To Depreciation | — | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | — | |
| Net Invested Capital | — | |
| Invested Capital | $ -33.00 M | |
| Net Tangible Assets | — | |
| Net Working Capital | — | |
| LIQUIDITY | ||
| Cash Ratio | — | |
| Current Ratio | — | |
| Current Ratio QoQ | — | |
| Current Ratio YoY | — | |
| Current Ratio IPRWA | — | |
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | — | |
| Cost Of Debt | 0.0 % | |
| Interest Coverage Ratio | — | |
| Interest Coverage Ratio QoQ | — | |
| Interest Coverage Ratio YoY | — | |
| Interest Coverage Ratio IPRWA | — | |
| Operating Cash Flow Ratio | — | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | — | |
| Revenue Growth | 20.504 % | |
| Revenue Growth QoQ | 0.0 % | |
| Revenue Growth YoY | 0.0 % | |
| Revenue Growth IPRWA | high: 71.991 % MESO: 20.504 % mean: 4.324 % median: 3.463 % low: -44.404 % |
|
| Earnings Growth | — | |
| Earnings Growth QoQ | — | |
| Earnings Growth YoY | — | |
| Earnings Growth IPRWA | — | |
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | — | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | — | |
| Return On Sales (ROS) | — | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | — | |
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ -15.69 M | |
| Free Cash Flow Yield | — | |
| Free Cash Flow Yield QoQ | — | |
| Free Cash Flow Yield YoY | — | |
| Free Cash Flow Yield IPRWA | — | |
| Free Cash Growth | 2.858 % | |
| Free Cash Growth QoQ | -126.297 % | |
| Free Cash Growth YoY | -181.401 % | |
| Free Cash Growth IPRWA | high: 124.18 % MESO: 2.858 % mean: -35.089 % median: -41.36 % low: -67.101 % |
|
| Free Cash To Net Income | — | |
| Cash Flow Margin | — | |
| Cash Flow To Earnings | — | |
| VALUE & RETURNS | ||
| Economic Value Added | — | |
| Return On Assets (ROA) | — | |
| Return On Assets QoQ | — | |
| Return On Assets YoY | — | |
| Return On Assets IPRWA | — | |
| Return On Capital Employed (ROCE) | — | |
| Return On Equity (ROE) | — | |
| Return On Equity QoQ | — | |
| Return On Equity YoY | — | |
| Return On Equity IPRWA | — | |
| DuPont ROE | — | |
| Return On Invested Capital (ROIC) | — | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | — | |
| Return On Invested Capital IPRWA | — | |